phleum pratense sublingual immunotherapy

Phleum pratense sublingual immunotherapy is a standardized allergen extract derived from Timothy grass pollen, developed by Asac Pharmaceutical Inmunology S.A. for the treatment of grass pollen-induced allergic rhinitis, rhinoconjunctivitis, and associated asthma. Administered as a liquid solution sublingually, the therapy is designed to induce immunological tolerance through a process of desensitization. The mechanism of action involves modulating the patient's immune response to Phleum pratense allergens, specifically by promoting the induction of regulatory T-cells (Tregs) and increasing the production of allergen-specific IgG4 antibodies, which compete with IgE to prevent mast cell and basophil degranulation. This shift from a Th2-mediated allergic response to a Th1/Treg-mediated tolerant state aims to reduce clinical symptoms and the need for rescue medication upon natural allergen exposure. The drug is currently being evaluated in a Phase II dose-finding study (DEDOG) to determine the optimal concentration for efficacy and safety in patients aged 12 to 50 years.

Other names

Timothy grass pollen allergen extractphleum pratense allergen extractPhleum pratense SLIT